Becton, Dickinson and Company (NYSE:BDX) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $228.44 and last traded at $226.88, with a volume of 931500 shares changing hands. The stock had previously closed at $227.15.

A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 price target on shares of Becton, Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Tuesday, October 31st. Cowen restated a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Barclays restated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $217.08.

The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The stock has a market cap of $52,026.93, a PE ratio of 24.05, a PEG ratio of 1.79 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same period last year, the business posted $2.12 EPS. The business’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s payout ratio is 62.80%.

In other news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the sale, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of BDX. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and during the 1st quarter valued at about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Becton, Dickinson and by 8.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares during the last quarter. Harfst & Associates Inc. lifted its holdings in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the last quarter. Finally, Financial Architects Inc lifted its holdings in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. Institutional investors and hedge funds own 88.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/becton-dickinson-and-bdx-hits-new-52-week-high-at-228-44.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.